Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer

Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer David J. Stewart Oncologist 2004; 9: 43-52 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the toxicity challenges that limit the use of standard platinum-based therapies in patients with NSCLC. Discuss the role of topotecan as monotherapy and in combination with other agents in the first-line and second-line treatment of patients with NSCLC and its favorable toxicity profile relative to platinum. Describe the importance of understanding resistance mechanisms to optimize the efficacy of antitumor therapies such as topotecan. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 22, 2004 Most Recent Review: Dec. 22, 2004* Most Recent Update: Dec. 22, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.